- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02448368
RDEA3170 Tablet and Capsule Bioavailability Study
November 17, 2017 updated by: Ardea Biosciences, Inc.
A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170
The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subject is able to understand the study procedures and the risks involved, and is willing to provide written informed consent before the first study-related activity.
- Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.
- Subject has a Screening serum urate level of 4 to 7 mg/dL.
- Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.
Exclusion Criteria:
- Subject has a history or suspicion of kidney stones.
- Subject has undergone major surgery within 3 months prior to Screening.
- Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1.
- Subject has clinically unacceptable physical examination, per the Investigator's judgment.
- Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment.
- Subject has Screening clinical safety laboratory parameters (serum chemistry [other than serum creatinine and serum urate], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator.
- Subject has a serum creatinine value above the upper limit of normal at the Screening visit.
- Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment.
- Subject has a history of cardiac abnormalities
- Subject cannot swallow multiple tablets or capsules.
- Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
RDEA3170, 5 mg (FN24), administered in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
|
Experimental: Treatment B
RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
|
Experimental: Treatment C
RDEA3170, 10 mg (FN25), administered in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
|
Experimental: Treatment D
RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
|
Experimental: Treatment E
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Other Names:
|
Experimental: Treatment I
RDEA3170, 10 mg (FN26), administered in the fasted state.
|
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Other Names:
|
Experimental: Treatment J
RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
|
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Other Names:
|
Experimental: Treatment K
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Other Names:
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Day 1, 5, 9, 13, 17
|
Cmax is the maximum observed concentration of a drug after administration
|
Day 1, 5, 9, 13, 17
|
Time of Occurrence of Maximum Observed Concentration (Tmax)
Time Frame: Day 1, 5, 9, 13, 17
|
Tmax is the time of occurrence of cmax
|
Day 1, 5, 9, 13, 17
|
Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)
Time Frame: Day 1, 5, 9, 13, 17
|
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
|
Day 1, 5, 9, 13, 17
|
Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)
Time Frame: Day 1, 5, 9, 13, 17
|
AUC 0-∞ is a meausre of total concentration from time zero to infinity
|
Day 1, 5, 9, 13, 17
|
Apparent Terminal Half-life (t1/2)
Time Frame: Day 1, 5, 9, 13, 17
|
t1/2 is a measure of apparent terminal half-life
|
Day 1, 5, 9, 13, 17
|
Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules
Time Frame: Day 1, 5, 9, 13, 17
|
Cmax is the maximum observed concentration of a drug after administration
|
Day 1, 5, 9, 13, 17
|
AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules
Time Frame: Day 1, 5, 9, 13, 17
|
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
|
Day 1, 5, 9, 13, 17
|
AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules
Time Frame: Day 1, 5, 9, 13, 17
|
AUC 0-∞ is a meausre of total concentration from time zero to infinity
|
Day 1, 5, 9, 13, 17
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamics (PD) Profile of RDEA3170
Time Frame: Day -1, 1, 5, 9, 13, 17
|
Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing.
Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose.
Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.
|
Day -1, 1, 5, 9, 13, 17
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: J Hall, MD, Ardea Biosciences, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2015
Primary Completion (Actual)
June 26, 2015
Study Completion (Actual)
January 29, 2016
Study Registration Dates
First Submitted
April 30, 2015
First Submitted That Met QC Criteria
May 15, 2015
First Posted (Estimate)
May 19, 2015
Study Record Updates
Last Update Posted (Actual)
August 20, 2018
Last Update Submitted That Met QC Criteria
November 17, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RDEA3170-111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on RDEA3170, 5 mg
-
Ardea Biosciences, Inc.Completed
-
Ardea Biosciences, Inc.Completed
-
AstraZenecaCompletedType 2 Diabetes | Albuminuria | HyperuricemiaUnited States
-
Ardea Biosciences, Inc.Completed
-
PfizerCompleted
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States